SCHEMBL4579112

SCHEMBL4579112

O=C(O)c1ccc2c(c1)CCCN2C(=O)OCc1cccnc1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 1/20 0.49
RAB9A P51151 1/20 0.49
L3MBTL1 Q9Y468 1/20 0.49
PDK1 Q15118 2/20 0.47
PDK2 Q15119 2/20 0.47
PDK3 Q15120 2/20 0.47
PDK4 Q16654 2/20 0.47
POLB P06746 1/20 0.47
HSD17B10 Q99714 1/20 0.47
CYP11B2 P19099 5/20 0.45
CYP11B1 P15538 3/20 0.45
KDM4C Q9H3R0 1/20 0.43
NAMPT P43490 1/20 0.42
HDAC8 Q9BY41 1/20 0.42
AVPR2 P30518 1/20 0.42
OXTR P30559 1/20 0.42
AVPR1A P37288 1/20 0.42
MAPK1 P28482 1/20 0.42
OPRK1 P41145 1/20 0.41
KDM4E B2RXH2 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4580814 0.90 PDK1 (0.52) NPC1RAB9AL3MBTL1PDK1PDK2
SCHEMBL18392314 0.88 RAB9A (0.63) NPC1RAB9AL3MBTL1PDK1PDK2
SCHEMBL8446706 0.82 NPC1 (0.72) NPC1RAB9AL3MBTL1PDK1PDK2
SCHEMBL4577475 0.79 HDAC1 (0.44) NPC1RAB9AL3MBTL1PDK1PDK2
SCHEMBL24890841 0.78 PDK1 (0.47) NPC1RAB9AL3MBTL1PDK1PDK2
SCHEMBL4577465 0.77 HDAC1 (0.63) HDAC8
SCHEMBL13349382 0.75 ALDH1A1 (0.64) NPC1RAB9AL3MBTL1PDK1PDK2
SCHEMBL27616400 0.75 NPC1 (0.84) NPC1RAB9AL3MBTL1POLBKDM4E
SCHEMBL18392313 0.74 PDK1 (0.50) PDK1PDK2PDK3PDK4HSD17B10
SCHEMBL29446549 0.73 NPC1 (0.69) NPC1RAB9AL3MBTL1HSD17B10MAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2007720-B1 BENZAMIDE DERIVATIVES AS INHIBITORS OF HISTONE DEACETYLASE METHYLGENE INC (CA) 2013-12-25 EP disclosed
US-8598168-B2 Inhibitors of histone deacetylase METHYLGENE INC. (CA) 2013-12-03 US disclosed
EP-2007720-A1 BENZAMIDE DERIVATIVES AS INHIBITORS OF HISTONE DEACETYLASE Methylgene, Inc. (CA) 2008-12-31 EP disclosed
US-20080132503-A1 Inhibitors of Histone Deacetylase METHYLGENE INC. (CA) 2008-06-05 US disclosed
US-20080132503-A1 Inhibitors of Histone Deacetylase METHYLGENE INC. (CA) 2008-06-05 US disclosed
US-20080132503-A1 Inhibitors of Histone Deacetylase METHYLGENE INC. (CA) 2008-06-05 US disclosed
WO-2007118137-A1 BENZAMIDE DERIVATIVES AS INHIBITORS OF HISTONE DEACETYLASE METHYLGENE INC. (CA) 2007-10-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080132503-A1 Inhibitors of Histone Deacetylase HDAC1, HDAC5, HDAC3 NPC1 1197/4885RAB9A 2909/4885L3MBTL1 1291/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.